Characteristics of equine mesenchymal stem cells derived from amnion and bone marrow: in vitro proliferative and multilineage potential assessment.
Authors: Lange-Consiglio A, Corradetti B, Meucci A, Perego R, Bizzaro D, Cremonesi F
Journal: Equine veterinary journal
Summary
# Editorial Summary Researchers compared mesenchymal stem cells (MSCs) harvested from equine amniotic membrane and bone marrow to determine which source might offer better potential for regenerative medicine applications. Both cell types expressed appropriate stromal cell markers, but amniotic membrane stromal cells (AMSCs) substantially outperformed bone marrow MSCs (BM-MSCs) in practically important ways: AMSCs doubled roughly three times faster (1.17 days versus 3.27 days), and demonstrated superior clonogenic capacity, requiring only 243 seeded cells to generate one fibroblast colony compared to 590 cells from bone marrow. Additionally, BM-MSCs failed to differentiate into glial cells and showed slower osteogenic differentiation, whereas AMSCs maintained broader multilineage plasticity. For practitioners considering cellular therapies, amniotic membrane represents a compelling alternative to bone marrow harvest—it requires only non-invasive collection from placental tissue, generates cells that can proliferate rapidly enough for practical timescales, and possesses greater differentiation flexibility, making it genuinely viable for both immediate autologous treatment and off-the-shelf allogeneic product development.
Read the full abstract on PubMed
Practical Takeaways
- •Amniotic membrane may offer a more practical cell source for regenerative medicine applications compared to bone marrow, requiring noninvasive collection and showing faster proliferation rates
- •The superior differentiation potential of amniotic-derived cells could expand therapeutic options for tissue repair and regeneration in equine patients
- •Off-the-shelf preparation potential of amniotic cells could reduce turnaround time and costs for cell-based therapies in clinical practice
Key Findings
- •Amniotic mesenchymal stem cells (AMSCs) had significantly faster doubling time than bone marrow MSCs (1.17 vs 3.27 days, P<0.05)
- •AMSCs demonstrated superior clonogenic capability compared to BM-MSCs (242.73 vs 590.15 cells required per colony, P<0.05)
- •BM-MSCs failed to differentiate into glial cells while AMSCs successfully differentiated into multiple lineages
- •Amniotic membrane represents a noninvasive, low-cost alternative source for equine MSCs suitable for allogenic and autologous therapies